Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 is an experimental, potentially transformative in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback